The FDA based its approval on evidence from the ongoing, non-randomized CheckMate-142 phase 2 study, for which researchers treated 119 patients with nivolumab plus ipilimumab.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
An increase in the appearance of colorectal cancer incidence in younger people has prompted the American Cancer Society to revise its current screening guidelines.
A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.
Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.
Atezolizumab, Cobimetinib Combination Failed to Improve Survival Versus Regorafenib in Relapsed Colorectal CancerJune 27, 2018
The IMblaze370 trial did not meet the primary endpoint.
Pembrolizumab Did Not Improve PFS or OS Compared With Paclitaxel in Relapsed Gastric or Gastroesophageal Junction CancerJune 27, 2018
Results from the KEYNOTE-061 were presented at ESMO World GI 2018.
Ramucirumab prolonged progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory hepatocellular carcinoma (HCC).
CORRECT and CONCUR trials demonstrated an improvement in OS for patients receiving regorafenib compared with placebo.
Researchers sought to determine if autophagy-related proteins are associated with survival among patients with CRC.
A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.
XP-treated patients with metastatic gastric cancer who had tumors expressing UCK2 and OPRT above a specific threshold survived longer than patients with lower levels of these biomarkers.
Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic SitesJune 22, 2018
In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.
The addition of an EGFR inhibitor to a chemotherapy regimen did not improve outcomes when it came to cancers of the esophagus.
The CRICKET trial is evaluating the third-line retreatment of patients with mCRC with cetixumab plus irinotecan.
Increasing the sensitivity cutoff from 5% to 1% in next-generation sequencing allowed for the identification of 28% more RAS/BRAF mutations.
A study reported post-hoc subgroup analyses of the international phase 3 NAPOLI-1 trial.
The OncoBEAM RAS kit for circulating tumor DNA (ctDNA) analysis of patients with metastatic colorectal cancer (mCRC) demonstrated high positive and negative agreement of RAS mutations detected by tumor tissue analysis.
The combination of nab-paclitaxel plus gemcitabine improved quality of life scores and increased time to deterioration compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
New findings bolster the case for the predictive utility of ARID1A mutations.
Adding Oxaliplatin to Capecitabine-Based Chemotherapy, Radiation May Not Improve Survival in Rectal CancerJune 19, 2018
Researchers randomly assigned 1090 patients with advanced rectal adenocarcinoma to 5 weeks of preoperative capecitabine-based chemoradiation followed by 6 cycles of capecitabine alone or with oxaliplatin.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
Find cancer treatment regimens for hepatocellular carcinoma, including drugs such as sorafenib (Nexavar) and chemotherapy/radiotherapy clinical trials.
In this randomized screening trial, patients with advanced adenomas detected by flex sigmoidoscopy (FSG) were at significantly increased risk of CRC compared to those with no adenomas.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Findings on the predictive nature of nodal response to neoadjuvant therapy from the American Association for Thoracic Surgery 98th Annual Meeting.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
- Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific
- Massage and Cancer
- Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer
- Biomarker-Based Blood Test May Extend Reach of CT Screening for Certain Lung Cancers